Context Capital Management LLC Makes New Investment in Karyopharm Therapeutics Inc. $KPTI

Context Capital Management LLC purchased a new position in Karyopharm Therapeutics Inc. (NASDAQ:KPTI) during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 62,995 shares of the company’s stock, valued at approximately $464,000.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. Baird Financial Group Inc. bought a new position in Karyopharm Therapeutics in the second quarter worth approximately $45,000. XTX Topco Ltd bought a new position in Karyopharm Therapeutics in the second quarter worth approximately $56,000. Bridgeway Capital Management LLC bought a new position in Karyopharm Therapeutics in the second quarter worth approximately $163,000. ADAR1 Capital Management LLC bought a new position in Karyopharm Therapeutics in the third quarter worth approximately $164,000. Finally, State Street Corp boosted its holdings in Karyopharm Therapeutics by 27.2% in the fourth quarter. State Street Corp now owns 58,942 shares of the company’s stock worth $434,000 after acquiring an additional 12,600 shares in the last quarter. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Stock Up 5.6%

KPTI stock opened at $9.50 on Friday. Karyopharm Therapeutics Inc. has a twelve month low of $3.65 and a twelve month high of $10.99. The stock’s 50 day moving average is $8.47 and its 200-day moving average is $7.67. The firm has a market capitalization of $215.30 million, a PE ratio of -0.63 and a beta of 0.83.

Karyopharm Therapeutics (NASDAQ:KPTI) last posted its earnings results on Thursday, May 14th. The company reported ($1.24) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.45) by $0.21. The company had revenue of $35.07 million during the quarter, compared to the consensus estimate of $31.40 million. On average, equities research analysts anticipate that Karyopharm Therapeutics Inc. will post -3.24 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on KPTI. Cantor Fitzgerald reiterated an “overweight” rating on shares of Karyopharm Therapeutics in a report on Tuesday. Piper Sandler reiterated an “overweight” rating and issued a $16.00 price target (up from $8.00) on shares of Karyopharm Therapeutics in a report on Monday, April 27th. Rodman & Renshaw upgraded Karyopharm Therapeutics to a “strong-buy” rating in a report on Tuesday, March 10th. Robert W. Baird cut their price target on Karyopharm Therapeutics from $21.00 to $15.00 and set an “outperform” rating on the stock in a report on Wednesday, March 25th. Finally, HC Wainwright raised their target price on Karyopharm Therapeutics from $8.00 to $13.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $17.17.

Karyopharm Therapeutics Profile

Karyopharm Therapeutics (NASDAQ: KPTI) is a clinical-stage biopharmaceutical company focused on discovering and developing novel first-in-class drugs that target the nuclear export protein XPO1. The company’s lead product, selinexor (marketed as XPOVIO), is an oral selective inhibitor of nuclear export (SINE) compound approved for treatment of multiple myeloma and diffuse large B-cell lymphoma. In addition to selinexor, Karyopharm’s pipeline includes second-generation SINE compounds and combination studies in solid tumors and hematologic malignancies.

Founded in 2008 and headquartered in Newton, Massachusetts, Karyopharm has built a research platform around modulation of nuclear export pathways.